Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Intrexon Corporation    XON

INTREXON CORPORATION

(XON)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/11/2019 11/12/2019 11/13/2019 11/14/2019 11/15/2019 Date
5.53(c) 5.01(c) 5.47(c) 5.61(c) 5.64(c) Last
667 323 1 971 099 1 097 525 1 500 518 1 155 211 Volume
-1.95% -9.40% +9.18% +2.56% +0.53% Change
More quotes
Financials (USD)
Sales 2019 106 M
EBIT 2019 -182 M
Net income 2019 -195 M
Debt 2019 200 M
Yield 2019 -
Sales 2020 68,0 M
EBIT 2020 -147 M
Net income 2020 -162 M
Debt 2020 176 M
Yield 2020 -
P/E ratio 2019 -4,46x
P/E ratio 2020 -5,50x
EV / Sales2019 10,5x
EV / Sales2020 16,1x
Capitalization 918 M
More Financials
Company
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company... 
More about the company
Surperformance© ratings of Intrexon Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on INTREXON CORPORATION
11/12INTREXON CORP : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
11/12INTREXON : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
11/12INTREXON CORP : Results of Operations and Financial Condition, Financial Stateme..
AQ
11/07INTREXON : Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 ..
PU
11/04INTREXON : to Announce Third Quarter Financial Results on November 12th
PR
10/31INTREXON CORP : Entry into a Material Definitive Agreement, Financial Statements..
AQ
09/16INTREXON CORP : Changes in Registrant's Certifying Accountant, Financial Stateme..
AQ
08/19INTREXON : ActoBio Therapeutics™ Receives IND Green Light for New Antigen-..
PU
08/09INTREXON : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
08/08INTREXON CORP : Results of Operations and Financial Condition, Regulation FD Dis..
AQ
08/08INTREXON : Reports Second Quarter and First Half 2019 Financial Results
PR
08/01INTREXON : to Announce Second Quarter and First Half 2019 Financial Results on A..
PR
07/01INTREXON : ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase..
PR
06/26INTREXON : Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-30..
PU
06/18INTREXON : and Surterra Wellness Partner in $100mm Deal to Advance Commercial Sc..
PR
More news
News in other languages on INTREXON CORPORATION

- No features available -

More news
Sector news : Biotechnology & Medical Research - NEC
11/14BEIGENE : FDA Gives Accelerated Approval to BeiGene's Brukinsa
DJ
11/14Walt Disney soars while Cisco disappoints
11/14THERMO FISHER SCIENTIFIC : Qiagen Shares Surge on Report Thermo Fisher Mulling D..
DJ
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart INTREXON CORPORATION
Duration : Period :
Intrexon Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTREXON CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 8,00  $
Last Close Price 5,64  $
Spread / Highest target 130%
Spread / Average Target 41,8%
Spread / Lowest Target 6,38%
EPS Revisions
Managers
NameTitle
Randal J. Kirk Chairman & Chief Executive Officer
Thomas Bostick Chief Operating Officer
Rick L. Sterling Chief Financial & Accounting Officer
Thomas David Reed Chief Science Officer
Dean Jonathan Mitchell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INTREXON CORPORATION-13.76%918
IQVIA HOLDINGS INC.26.11%28 427
LONZA GROUP33.77%25 529
CELLTRION, INC.--.--%20 414
SEATTLE GENETICS, INC.102.52%19 667
INCYTE CORPORATION36.34%18 675